close
close

CFO Jane Henderson sells 6,000 shares of Apogee Therapeutics Inc (APGE)


CFO Jane Henderson sells 6,000 shares of Apogee Therapeutics Inc (APGE)

On August 23, 2024, Jane Henderson, Chief Financial Officer of Apogee Therapeutics Inc (NASDAQ:APGE), sold 6,000 shares of the company at a price of $48.26 per share. The transaction was documented in an SEC filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc.

Apogee Therapeutics Inc. is engaged in the development and commercialization of various therapies to treat diseases with significant unmet medical needs. The company is focused on a pipeline of novel therapeutic products.

Over the past year, insider transaction history at Apogee Therapeutics Inc. shows a total of 5 insider sales and no insider purchases. Insider Jane Henderson sold a total of 6,000 shares and bought no shares during this period.

Apogee Therapeutics Inc. shares were trading at $48.26 on the day of the transaction, giving the company a market capitalization of approximately $2.74 billion. This valuation reflects the company’s current price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow ratio.

The following insider trend image provides a visual representation of recent insider transactions at Apogee Therapeutics Inc.:

Insider sale: CFO Jane Henderson sells 6,000 shares of Apogee Therapeutics Inc (APGE)Insider sale: CFO Jane Henderson sells 6,000 shares of Apogee Therapeutics Inc (APGE)

Insider sale: CFO Jane Henderson sells 6,000 shares of Apogee Therapeutics Inc (APGE)

For more detailed valuation metrics, such as Apogee Therapeutics Inc.’s GF Value, investors and shareholders are requested to visit the links provided.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.

Leave a Reply

Your email address will not be published. Required fields are marked *